2011-000501-52: PARAGON - Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms |
|
|
| Ongoing | 2 | 150 | Europe | Anastrazole (Arimidex), Arimidex, Arimidex | Greater Glasgow and Clyde, University of Glasgow, , Cancer Research UK, AstraZeneca UK | Patients with potentially hormone responsive recurrent or metastatic gynaecological cancers from following subgroups:A - Epithelial ovarian cancer, primary peritoneal cancers and cancers of the fallopian tubeB- Endometrial cancerC- Endometrial Stromal SarcomasD- Miscellaneous SarcomasE- Granulosa Cell Tumours and other Sex Tumours * UK sites will only enter patients to subgroups B-E * | | | | |
BFR-ESS, NCT03624244: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) |
|
|
| Recruiting | 2 | 40 | Europe | Aromatase Inhibitors, ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE | Centre Leon Berard | Low Grade Endometrial Stromal Sarcoma | 01/25 | 01/28 | | |
